What are the peri‑operative management recommendations for colchicine and the anesthesia considerations, including drug interactions and neuromuscular blocker selection?

Perioperative Management of Colchicine and Anesthesia

Continue colchicine at the usual maintenance dose throughout the perioperative period without interruption, as discontinuation risks disease flare without improving surgical safety. 1

Key Perioperative Principles

The most recent EULAR/PReS guidelines (2025) explicitly recommend continuing colchicine during surgical procedures, mirroring the guidance for pregnancy and lactation 1. This represents a shift from older practices of stopping anti-inflammatory medications perioperatively.

Rationale for Continuation

• Colchicine withdrawal precipitates inflammatory attacks in FMF and other conditions
• No evidence supports perioperative discontinuation improving outcomes
• The drug's anti-inflammatory effects may actually benefit postoperative recovery 2
• Stable therapeutic levels prevent disease destabilization

Critical Drug Interactions During Anesthesia

High-Risk Anesthetic Drug Combinations

Avoid or use extreme caution with CYP3A4/P-glycoprotein inhibitors, as these can increase colchicine levels by 200-300%, potentially causing life-threatening toxicity 3:

Absolutely contraindicated perioperatively:

• Clarithromycin (increases colchicine levels 227-282%) 4
• Ketoconazole (increases levels 102-212%) 4
• Cyclosporine (increases levels 259-270%) 4

Use with dose reduction (50% colchicine dose):

• Verapamil (increases levels 40-103%) 4
• Diltiazem (increases levels 44-93%) 4

Safer alternatives:

• Azithromycin shows minimal interaction (22-57% increase) 4
• Most anesthetic induction agents (propofol, volatile anesthetics) have no documented interactions

Common Pitfall

Many anesthesiologists reflexively prescribe prophylactic antibiotics like clarithromycin or use calcium channel blockers for blood pressure control without checking for colchicine interactions. Always verify the patient's medication list and choose alternative agents.

Neuromuscular Blocker Considerations

Critical Safety Issue: Colchicine and Muscle Relaxants

Colchicine causes neuromuscular toxicity by disrupting microtubule function 3, creating several anesthetic concerns:

Specific recommendations for neuromuscular blockade:

1. Avoid succinylcholine if possible - While not explicitly contraindicated, colchicine's effects on muscle cells theoretically increase hyperkalemia risk

2. Use rocuronium as first-line NMBD 5:

   • Dose: 0.9-1.2 mg/kg for rapid sequence intubation
   • Allows sugammadex reversal (see below)
   • Predictable pharmacokinetics

3. Mandatory quantitative neuromuscular monitoring 5:

   • Use train-of-four (TOF) monitoring at the adductor pollicis
   • Target TOF ratio >0.9 before extubation
   • Colchicine patients may have baseline neuromuscular dysfunction

4. Reversal strategy - Strongly prefer sugammadex 5:

   • Can reverse deep, moderate, or shallow blockade from rocuronium/vecuronium
   • More reliable than neostigmine in patients with potential neuromuscular compromise
   • If using neostigmine: wait until TOF >0.2, continue monitoring until TOF >0.9

Warning Signs of Colchicine Neuromuscular Toxicity

Monitor for these perioperatively 4:

• Muscle weakness (may manifest as difficulty weaning from ventilator)
• Prolonged paralysis after standard NMBD doses
• Tingling or numbness in extremities
• Elevated creatine kinase

If suspected, discontinue colchicine immediately and provide supportive care - no specific antidote exists 3.

Hepatic and Renal Considerations

Dose Adjustments Based on Organ Function

Renal impairment 4:

• End-stage renal disease: 75% reduction in clearance, half-life prolonged to 18.8 hours
• Moderate-severe impairment: reduce dose by 50%
• Dialysis does NOT remove colchicine effectively

Hepatic impairment 4:

• Mild-moderate cirrhosis: significantly reduced clearance, prolonged half-life
• Severe hepatic impairment (Child-Pugh C): no pharmacokinetic data available; use minimum effective dose with extreme caution
• Primary biliary cirrhosis: unpredictable, highly variable clearance

Perioperative Monitoring Strategy

For patients with organ dysfunction on colchicine:

• Obtain baseline CBC, CK, liver enzymes, creatinine
• Daily monitoring for first 3 postoperative days
• Watch for signs of toxicity: diarrhea, abdominal pain, cytopenias

Colchicine Toxicity Recognition

Three-Stage Toxicity Syndrome 3

Stage 1 (0-24 hours):

• Cholera-like diarrhea, vomiting, abdominal cramping
• Dehydration, shock
• Acute renal failure, seizures

Stage 2 (24-72 hours):

• Multiorgan failure
• Bone marrow suppression (agranulocytosis, thrombocytopenia)
• ARDS, arrhythmias
• DIC, coma, death

Stage 3 (weeks):

• Recovery phase with rebound leukocytosis
• Alopecia
• Resolution of organ failure

Management is purely supportive - no effective means to remove colchicine from tissues. F(ab) antibody fragments exist but are not generally available 3.

Practical Perioperative Algorithm

Preoperative (1-7 days before surgery):

1. Continue usual colchicine dose
2. Review all medications for CYP3A4/P-gp inhibitors
3. Obtain baseline labs if organ dysfunction present
4. Document baseline neuromuscular function

Intraoperative:

1. Give morning colchicine dose as scheduled
2. Use rocuronium for muscle relaxation
3. Implement quantitative TOF monitoring
4. Avoid clarithromycin, ketoconazole, cyclosporine
5. Choose azithromycin if antibiotic prophylaxis needed

Postoperative:

1. Resume colchicine at usual dose once oral intake tolerated
2. Use sugammadex for NMBD reversal
3. Ensure TOF >0.9 before extubation
4. Monitor for neuromuscular weakness
5. Watch for GI symptoms suggesting toxicity

Special Populations

Elderly patients (≥65 years) 4:

• More frequent renal impairment
• Consider empiric 50% dose reduction if CrCl <50 mL/min
• Increased sensitivity to drug interactions

Cardiac surgery patients 6, 2:

• Emerging evidence suggests colchicine may reduce postoperative atrial fibrillation, pericardial effusions, and post-pericardiotomy syndrome
• Continue perioperatively; may provide additional benefit
• Typical regimen: 0.5 mg daily or every other day postoperatively

Bottom Line

The evidence strongly supports continuing colchicine perioperatively at maintenance doses, using rocuronium with quantitative monitoring and sugammadex reversal, and meticulously avoiding CYP3A4/P-gp inhibitors. The risk of disease flare from discontinuation outweighs theoretical surgical concerns, and modern anesthetic techniques allow safe management when drug interactions are respected.